Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)

NCT03866798 is registered in ClinicalTrials.gov with Octapharma as lead sponsor.

NCT NCT03866798
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03866798 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Study to Evaluate the Efficacy and Safety of PANZYGA in Pediatric Patients With Chronic Immune Thrombocytopenia (ITP)
Lead sponsor
Octapharma
Phase
Phase 4
Overall status
Terminated
Start date
January 21, 2020
Completion date
May 17, 2024
Enrollment
6 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

chronic immune thrombocytopenia